NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

Guidewire Beats Revenue & EPS Forecasts, But Stock Falls on Full-Year ARR Outlook

Guidewire beat Q3 earnings, but a weak ARR outlook worried investors, sending shares down despite strong revenue growth.

Guidewire Beats Revenue & EPS Forecasts, But Stock Falls on Full-Year ARR Outlook
Credit: Tada Images/Shutterstock
Already have an account? Sign in.
06/05/2026 · 6:38 AM
GWRE
/ Read more

Feed↓

Roth Capital Initiates Coverage on COYA With Buy Rating and Huge ALS Potential
06/05/2026 · 7:29 AM

Roth Capital Initiates Coverage on COYA With Buy Rating and Huge ALS Potential

COYA gets Buy rating; ALS drug COYA 302 shows early promise, could double stock if trials succeed, high risk biotech.

/ Subscriber only
Shattuck Labs Stock Gets Bullish Citi Upgrade Before SL-325 Phase 1 Results
06/05/2026 · 7:10 AM

Shattuck Labs Stock Gets Bullish Citi Upgrade Before SL-325 Phase 1 Results

Citi upgrades STTK to Buy with $7 price target and 30-day upside watch ahead of SL-325 Phase 1 data in Q2 2026.

/ Subscriber only
Biogen’s Salanersen Wins FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
06/05/2026 · 6:12 AM

Biogen’s Salanersen Wins FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

Biogen’s new SMA drug Salanersen shows strong early results, helping kids move better. FDA fast-tracks it with Breakthrough status.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2026
Email address Subscribe